

Raziel Therapeutics (Yissum)

code: 6-2013-2894

Shmuel Ben-Sasson, HUJI, Faculty of Medicine, Experimental medicine and cancer research

Investment/ Collaboration Opportunity Highlights:

Raziel therapeutics was founded in 2012 and raised money from privet leader investors in round A.

About the company

Raziel therapeutics is innovative company dedicated to address unmet needs in the rapidly-growing market for obesity disease.

Raziel Therapeutics has developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like.

It is well known that the function of WAT is to store fat, while that of BAT is to burn fat for heat production. Therefore, WAT to BAT conversion is considered a preferred strategy to treat obesity and overweight disease.

Our products

Prof. Muli Ben-Sasson and his team discovered that among novel molecules they synthesized, there is a family of compounds that are able to influence the fate of fat-tissue cells (=adipocytes), dramatically.

An investigation of their mechanism of action illustrates these molecules are able to convert white-adipose-tissue (WAT) into brown-adipose tissue like (BAT), as evident by the morphology and molecular markers of the treated adipose-tissue.

The company product candidate, RZL-12, is a potential first-in-class, injectable drug currently in Pre-clinical development for the reduction of fat cell mass. The feasibility of its oral formulation is now under investigation.

Development Milestones

The company is in pre-clinical stage and intend to be in clinical stage in Q2, 2014.



Contact details

alon@raziel-therapy.com

Contact for more information:

Ariela Markel ☑, VP, Business Development, Healthcare, +972-2-6586608

Yissum Research Development Company of the Hebrew University of Jerusalem Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390 Israel Telephone: 972-2-658-6688, Fax: 972-2-658-6689